About Abiraxen 250 mg Tablet
Everest Pharmaceuticals Ltd. makes Abiraxen 250 mg tablets, containing abiraterone acetate. It is a cytotoxic chemotherapy medicine used in prostate cancer treatment under specialist care.
There are 4 brands of Abiraterone Acetate listed in Bangladesh. 2 of them have a lower unit price than Abiraxen. The lowest listed price is Abiret 250 mg Tablet at ৳ 500.00 per unit.
What is Abiraxen 250 mg Tablet?
Abiraxen is a tablet medicine manufactured by Everest Pharmaceuticals Ltd. Its active ingredient is abiraterone acetate, and each tablet has a strength of 250 mg. It belongs to a group of medicines called cytotoxic chemotherapy. It works by blocking an enzyme in the body that helps make androgens, which are hormones that can support prostate cancer growth. Doctors use it as part of treatment for certain stages of prostate cancer, always alongside other medicines and under specialist supervision. Treatment and monitoring are arranged by the treating doctor.
Uses of Abiraxen
Abiraxen is used in adults with prostate cancer that has spread, in two situations: cancer that no longer responds to castration treatment, and high-risk cancer that still responds to castration. It is given together with prednisone and, where appropriate, another hormone treatment or after surgery to remove the testes. Only a specialist doctor can decide whether this medicine is suitable.
How to use Abiraxen
Swallow the tablet whole with water; do not crush or chew it. Take it on an empty stomach, at least one hour before or two hours after a meal. The doctor decides the dose, the timing and how long treatment continues, and may change the plan based on blood tests and your condition. Do not start, stop or change the medicine on your own. Ask your doctor or pharmacist if you are unsure how to take it.
Side effects of Abiraxen
Common side effects include tiredness, joint pain, high blood pressure, nausea, swelling, low potassium, hot flushes, diarrhoea, vomiting, upper respiratory infection, cough and headache. Some people may have more serious problems affecting the liver, blood pressure, potassium levels or hormone balance. Tell your doctor promptly about any new or worsening symptoms. Your doctor will arrange checks during treatment. Ask your doctor or pharmacist about anything you notice.
Safety and precautions
Before starting Abiraxen, tell your doctor about heart disease, high blood pressure, low potassium, liver problems or previous hormone-related illness, because monitoring and extra care may be needed. This medicine is not for women; it can harm a pregnancy and safety in females has not been established. It should not be used during breastfeeding. Do not use it if you are allergic to abiraterone acetate or any other ingredient. Tell your doctor about all other medicines you take, as some can interact. The doctor will decide on monitoring and any dose changes.
Frequently asked questions
What is Abiraxen used for and what kind of medicine is it?
Abiraxen is a cytotoxic chemotherapy medicine containing abiraterone acetate. It is used in adults with certain stages of spread prostate cancer, together with prednisone and sometimes other hormone treatment. Only a specialist doctor can decide if it is right for you.
How should Abiraxen be taken?
Swallow the tablet whole with water on an empty stomach, at least one hour before or two hours after food. Do not crush or chew it. The doctor decides the dose, timing and length of treatment, and may adjust the plan after checks. Never change the medicine yourself.
What do the tablet form and 250 mg strength mean?
Abiraxen comes as a tablet, which is a solid oral dosage form you swallow. The strength of 250 mg means each tablet contains 250 mg of abiraterone acetate. The doctor decides how the medicine is used for your treatment.
What is the price of Abiraxen?
The listed price is ৳ 580.00. Your pharmacy can confirm availability and any dispensing charges. Ask your doctor or pharmacist if you need help understanding the cost of your treatment.
- Strength
- 250 mg
Price in Bangladesh
৳ 568.4 ৳ 580.00 2% off unit price
Price updated: 18 Nov 2026
Indications
Abiraxen is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with
- Metastatic castration-resistant prostate cancer (CRPC).
- Metastatic high-risk castration-sensitive prostate cancer (CSPC).
Pharmacology
Abiraterone Acetate is converted in vivo to Abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17, 20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions:
1. The conversion of pregnenolone and progesterone to their 17 α-hydroxy derivatives by 17 α-hydroxylase activity and
2. The subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20 lyase activity. DHEA and androstenedione are androgens and are precursors of testosterone. Inhibition of CYP17 by Abiraterone can also result in increased mineralocorticoid production by the adrenals. Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor.
Abiraterone Acetate decreased serum testosterone and other androgens in patients in the placebo-controlled clinical trial. It is not necessary to monitor the effect of Abiraterone Acetate on serum testosterone levels. Changes in serum prostate specific antigen (PSA) levels may be observed but have not been shown to correlate with clinical benefit in individual patients.
Dosage & Administration
Recommended Dose For Metastatic CRPC: The recommended dose of Abiraterone Acetate is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with Prednisone 5 mg orally twice daily.
Recommended Dose For Metastatic High-Risk CSPC: The recommended dose of Abiraterone Acetate is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with Prednisone 5 mg administered orally once daily.
Patients receiving Abiraterone Acetate should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Abiraterone Acetate must be taken on an empty stomach, at least one hour before or at least two hours atier a meal. The tablets should be swallowed whole with water. Do not crush or chew tablets.
Dose Modification:
- For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the Abiraterone Acetate starting dose to 250 mg once daily.
- For patients who develop hepatotoxicity during treatment, hold Abiraterone Acetate until recovery. Retreatment may be initated at a reduced dose. Abiraterone Acetate should be discontinued if patients develop severe hepatotoxicity.
- Avoid concomitant strong CYP3A4 inducers (e.g., Phenytoin, Carbamazepine, Rifampin, Rifabutin, Rifapentine, Phenobarbital) during Abiraterone Acetate treatment. If a strong CYP3A4 inducer must be co-administered, increase the Abiraterone Acetate dosing frequency to twice a day only during the co-administration period (e.g., from 1,000 mg once daily to 1,000 mg twice a day). Reduce the dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued. Or, as directed by the registered physician.
Pediatric Use: The safety and effectiveness in pediatric patients have not been established.
Interaction
Drugs That Inhibit Or Induce CYP3A4 Enzymes: Based on in vitro data, Abiraxen is a substrate of CYP3A4. In a dedicated drug interaction trial, co-administration of Rifampin, a strong CYP3A4 inducer, decreased exposure of Abiraxen by 55%. Avoid concomitant strong CYP3A4 inducers during Abiraxen treatment. If a strong CYP3A4 inducer must be co-administered, increase the Abiraxen dosing frequency. In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of Abiraxen.
Effects Of Abiraxen On Drug Metabolizing Enzymes: Abiraxen is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug-drug interaction trial, the Cmax and AUC of Dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when Dextromethorphan was given with Abiraxen 1,000 mg daily and Prednisone 5 mg twice daily. Avoid co-administration of Abiraxen with substrates of CYP2D6 with a narrow therapeutic index (e.g., Thioridazine). If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug. In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of Pioglitazone (CYP2C8 substrate) was increased by 46% when Pioglitazone was given together with a single dose of 1,000 mg Abiraxen. Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with Abiraxen.
Contraindications
Hypersensitivity to the Abiraterone acetate or to any of the excipients of Abiraterone.
Side Effects
The most common adverse reactions are fatigue, arthalgia, hypertension, nausea, edema, hypokalemia, hot flush, diarrhea, vomiting, upper respiratory infection, cough, and headache.
Pregnancy & Lactation
The safety and efficacy of Abiraterone have not been established in females. Based on findings from animal studies and the mechanism of action, Abiraterone can cause fetal harm and potential loss of pregnancy. There are no human data on the use of Abiraterone in pregnant women. The safety and efficacy of Abiraterone have not been established in females. There is no information available on the presence of abiraterone acetate in human milk, or on the effects on the breastfed child or milk production.
Precautions & Warnings
Abiraxen may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Patients should be monitored for hypertension, hypokalemia, and fluid retention at least once a month. Hypertension and hypokalemia should be controlled and corrected before and during treatment with Abiraxen. Patients should be monitored for symptoms and signs of adrenocortical insufficiency. Serum transaminases (ALT and AST) and bilirubin levels should be measured prior to starting treatment with Abiraxen, every two weeks for the first three months of treatment and monthly thereatier.
Overdose Effects
There is no specific antidote. In the event of an overdose, Abiraxen should be stopped, general supportive measures are undertaken, including monitoring for arrhythmias and cardiac failure and assess liver function.
Storage Conditions
Do not store above 25°C. Protect from light. Keep out of the reach of children.
Alternative brands of Abiraterone Acetate
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.